10 completed, 10 terminated, 1 withdrawn. 21 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 10, Terminated 10, Withdrawn 1 |
| Phase 2 | 4 | Terminated 3, Completed 1 |
Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents Idelalisib, Rituximab, Ifosfamide - Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma | Phase 1 | Withdrawn | Gilead Sciences | 2019-06-01 | 2018-12-11 | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Idelalisib 100 MG, Placebo Oral Tablet - B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2018-07-31 | 2024-03-12 |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia Idelalisib - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | PETHEMA Foundation | 6 | 2018-07-01 | 2021-09-05 |
| Pembrolizumab + Idelalisib for Lung Cancer Study Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis | Phase 1 / Phase 2 | Terminated | Asha Nayak | 4 | 2017-09-26 | 2024-02-28 |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL ACY-1215, Ibrutinib, Idelalisib - Recurrent Chronic Lymphoid Leukemia | Phase 1 | Completed | Dana-Farber Cancer Institute | 3 | 2016-05-01 | 2026-11-12 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia Idelalisib, BI 836826 - Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Terminated | Gilead Sciences | 2 | 2015-12-29 | 2020-11-25 |
| Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL BCL201, Idelalisib - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Completed | Novartis Pharmaceuticals | 20 | 2015-11-16 | 2020-02-24 |
| Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma Idelalisib, Nab-paclitaxel, mFOLFOX6 - Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma | Phase 1 | Terminated | Gilead Sciences | 16 | 2015-07-30 | 2021-04-02 |
| Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Tirabrutinib, Idelalisib, Entospletinib - B-cell Malignancies | Phase 1 | Terminated | Gilead Sciences | 203 | 2015-06-16 | 2025-06-17 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease Idelalisib, Ruxolitinib - Myelofibrosis | Phase 1 | Terminated | Gilead Sciences | 10 | 2015-06-05 | 2020-09-16 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) Idelalisib - Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma | Phase 1 | Completed | Gilead Sciences | 6 | 2014-10-01 | 2021-03-19 |
| Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma lenalidomide, idelalisib - Relapsed/Refractory Mantle Cell Lymphoma | Phase 1 | Completed | Alliance for Clinical Trials in Oncology | 106 | 2013-10-17 | 2026-06-16 |
| Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma idelalisib, lenalidomide - Recurrent Follicular Lymphoma | Phase 1 | Completed | Alliance for Clinical Trials in Oncology | 8 | 2013-08-02 | 2026-06-16 |
| Phase 1b Safety and Efficacy Study of TRU-016 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab - Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma | Phase 1 | Terminated | Aptevo Therapeutics | 87 | 2012-09-01 | 2021-05-20 |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Idelalisib - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Gilead Sciences | 18 | 2011-02-01 | 2018-11-19 |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Idelalisib, Rituximab, Bendamustine - Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Gilead Sciences | 241 | 2010-03-25 | 2021-03-18 |
| An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 202 | 2010-03-22 | 2019-08-28 |
| Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber CAL-101, Placebo - Allergic Rhinitis | Phase 1 | Completed | Gilead Sciences | 41 | 2009-02-01 | 2018-10-23 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Lymphoma, B-Cell, Marginal Zone (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Primary Myelofibrosis (2) · Recurrence (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Gilead Sciences (11) · Alliance for Clinical Trials in Oncology (2) · OHSU Knight Cancer Institute (2) · Aptevo Therapeutics (1) · Asha Nayak (1) · Dana-Farber Cancer Institute (1) · Novartis Pharmaceuticals (1) · PETHEMA Foundation (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (17) · France (3) · Austria (2) · Spain (2) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · United Kingdom (1)
Douglas Gladstone, MD (1) · Friedrich Horak, MD (1) · Jennifer B Brown, MD, PhD (1) · John P. Leonard, MD (1) · Lara Davis, MD (1) · Scott C. Stromatt, M.D. (1) · Sonali Smith, MD (1) · Stephen Spurgeon (1) · Zhonglin Hao, MD, PhD (1)
PMID 21816833, PMID 24615776, PMID 24615777, PMID 24615778, PMID 28314699, PMID 29296805, PMID 31723767, PMID 26472751, PMID 26915677, PMID 28178345, PMID 32856068, PMID 39863139
U10CA031946 (2), 2015 (1), 2017 (1), P30CA069533 (1)